AbbVie Announces Tavapadon Meets Primary Endpoint in Phase 3 Trial for Early-Stage Parkinson’s Disease

Gelonghui September 26 | AbbVie Inc. announced on Thursday that Tavapadon met the primary endpoint in a pivotal Phase 3 clinical trial for the treatment of patients with early-stage Parkinson's disease.